Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Fig. 3

Down-regulated HHLA2 was associated with CD8+CD103+TRM enrichment. (A) Comparison of negative regulation of immune response, T cell proliferation, and CD8+T cell activation gene sets from the MSigDB database based on TCGA in the HHLA2low and HHLA2high group. (B) Representative flow cytometry chart of CD8+CD103+TRM in the HHLA2low versus HHLA2high group. (C) Representative flow cytometry chart of GZMB, IFNG, PD1 among CD8+CD103+TRM in the HHLA2low versus HHLA2high group. (D) Statistical maps of CD8+CD103+TRM proportion and function in the HHLA2low versus HHLA2high group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page